Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Fumarate SCHEMBL11470776 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL1902730 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL9435698 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL1905731 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL6440837 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL1904369 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL1904374 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL1903287 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL20594713 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 | |
| Ethyl Fumarate SCHEMBL5016627 | 0.95 | HCAR2 (0.61) | HCAR2MAPTATMNPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110898164-A | Monoethyl fumarate calcium salt for eradicating gastrointestinal disease helicobacter pylori infection and application thereof | 赣州安宏环保科技有限公司 | 2020-03-24 | — | — | CN | claimed |
| US-RE50049-E1 | Compositions and methods for treating psoriasis | SYTHEON LTD. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | ARBOR PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | ARBOR PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| EP-3273951-B1 | COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | SYMBIONYX PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-20140056978-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140056973-A1 | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031897-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF (N,N- DIETHYLCARBAMOYL)METHYL METHYL|(2E)BUT-2-ENE-1,4-DIOATE | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031892-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031894-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | WILSHIRE PHARMACEUTICALS, INC. | 2013-12-05 | — | — | US | disclosed |
| WO-2013181451-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XENOPORT, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-6858750-B2 | Use of fumaric acid derivatives for treating mitochondrial diseases | FUMAPHARM AG (CH) | 2005-02-22 | — | — | US | disclosed |
| US-6277882-B1 | SKIN DISORDERS | FUMAPHARM AG (CH) | 2001-08-21 | — | — | US | disclosed |
| JP-2000178116-A | SKIN COSMETIC | KANEBO LTD | 2000-06-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | HCAR2 442/4885MAPT 1557/4885ATM 2577/4885 |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | HCAR2 442/4885MAPT 1557/4885ATM 2577/4885 |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | HCAR2 788/4885MAPT 3460/4885ATM 2734/4885 |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | MGMT, MTHFD2, PHF2 | HCAR2 92/4885MAPT 1938/4885ATM 4199/4885 |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | HCAR2 128/4885MAPT 1286/4885ATM 4292/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | HCAR2 442/4885MAPT 1557/4885ATM 2577/4885 |
| US-20140056973-A1 | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug | FH, MGMT, CYP4F2 | HCAR2 788/4885MAPT 3460/4885ATM 2734/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | HCAR2 442/4885MAPT 1557/4885ATM 2577/4885 |
| US-20140056978-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | FH, MGMT, BHMT2 | HCAR2 320/4885MAPT 1322/4885ATM 3328/4885 |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | HCAR2 128/4885MAPT 1286/4885ATM 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.